Skip to main content

Table 5 Biologic pathways that distinguish or are shared between SJIA ESR and SJIA JC

From: Correlation analyses of clinical and molecular findings identify candidate biological pathways in systemic juvenile idiopathic arthritis

IPA Canonical Pathways

-Logarithm

(P-value)

Difference

(ESR-JC)

Gene expression with higher ESR/JC*

 

SJIA ESR

SJIA JC

  

Glucocorticoid receptor signaling

5.68

3.07

2.61

Higher (both)

PI3K/AKT signaling

1.27

3.73

-2.45

Higher (both)

Role of PKR in interferon induction and antiviral response

4.43

4.43

0

Higher (both)

Altered T cell and B cell signaling in rheumatoid arthritis

3.91

3.91

0

Higher (both)

T helper cell differentiation

3.74

3.74

0

Lower (both)

iCOS-iCOSL signaling in T helper cells

3.73

3.73

0

Lower (both)

CD40 signaling

3.73

3.73

0

Lower (both)

MIF regulation of innate immunity

3.70

3.70

0

Higher (both)

LPS-stimulated MAPK signaling

3.42

3.42

0

Higher (both)

CD27 signaling in lymphocytes

3.18

3.18

0

Higher (both)

MIF-mediated glucocorticoid regulation

3.02

3.02

0

Higher (both)

Role of cytokines in mediating communication between immune cells

3.01

3.01

0

Higher (both)

TREM1 signaling

2.91

2.91

0

Higher (both)

Crosstalk between dendritic cells and natural killer cells

2.81

2.81

0

Lower (both)

Docosahexaenoic acid (DHA) signaling

2.76

2.76

0

Higher (both)

Regulation of IL-2 expression in activated and anergic T lymphocytes

2.39

2.39

0

Higher (both)

Toll-like receptor signaling

2.37

2.37

0

Lower (both)

fMLP signaling in neutrophils

2.33

2.33

0

Higher (both)

TNFR1 signaling

2.22

2.22

0

Higher (both)

RANK signaling in osteoclasts

2.16

2.16

0

Lower (both)

4-1BB signaling in T lymphocytes

2.12

2.12

0

Higher (both)

CD28 signaling in T helper cells

2.11

2.11

0

Lower (both)

Communication between innate and adaptive immune cells

2.06

2.06

0

Higher (both)

T cell receptor signaling

2.03

2.03

0

Lower (both)

ILK signaling

2.01

2.01

0

Higher (both)

  1. * in ≥ 50% of the genes in the pathway; in comparison to lower ESR/JC.